Triple-negative breast cancers, which are more frequently diagnosed in younger women, are a subtype of breast tumor characterized by the absence of hormone receptors and HER2 overexpression. As a result, they do not respond to hormone therapy or HER2-targeted treatments. Their prognosis is generally less favorable than that of other breast cancer subtypes.
❓ Unknown
Potential of Immunotherapy in Treating Early-Stage Triple-Negative Breast Cancer
Just now
October 27, 2026
1 min read
📰 Medical Xpress
📋 Key Takeaway
The article discusses the challenges of treating triple-negative breast cancer, a subtype prevalent among younger women, due to its lack of hormone receptors and HER2 overexpression. This cancer type has a poorer prognosis, highlighting the need for innovative treatment approaches like immunotherapy. Understanding these developments is crucial for Iran as it navigates healthcare advancements and cancer treatment options.
🌐
Translated from the original and edited for English readers. View original source →
Translation confidence: 100%
📰 Related Coverage
Just now •
Three Executed in Isfahan: A Woman for Murder and Two Men for Drug Offenses
Just now •
Mohsen Rezai: We Agreed in the Quadrilateral Meeting that Regional Security Must Be Endogenous Without…
1 min ago •
The Next $15 Trillion Energy Market in the World
11 min ago •
Saffron; From the Iranian Table to Dispelling Misfortunes!
13 min ago •